Mineralys Therapeutics Analyst Ratings
Mineralys Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/08/2023 | 196% | Credit Suisse | $38 → $37 | Maintains | Outperform |
| 05/16/2023 | 204% | Credit Suisse | → $38 | Reiterates | Outperform → Outperform |
| 03/16/2023 | 204% | Credit Suisse | $40 → $38 | Maintains | Outperform |
| 03/07/2023 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
| 03/07/2023 | 116% | Wells Fargo | → $27 | Initiates Coverage On | → Overweight |
| 03/07/2023 | 220% | Credit Suisse | → $40 | Initiates Coverage On | → Outperform |
| 03/07/2023 | 156% | Guggenheim | → $32 | Initiates Coverage On | → Buy |
| 03/07/2023 | 212% | B of A Securities | → $39 | Initiates Coverage On | → Buy |
| 03/07/2023 | 260% | Stifel | → $45 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023/08/08 | 196% | 瑞士信貸 | $38→$37 | 維護 | 跑贏大盤 |
| 2023年05月16日 | 204% | 瑞士信貸 | →$38 | 重申 | 跑贏→跑贏大盤 |
| 03/16/2023 | 204% | 瑞士信貸 | $40→$38 | 維護 | 跑贏大盤 |
| 03/07/2023 | - | Evercore ISI集團 | 開始承保 | →跑贏大盤 | |
| 03/07/2023 | 116% | 富國銀行 | →$27 | 開始承保 | →超重 |
| 03/07/2023 | 220% | 瑞士信貸 | →$40 | 開始承保 | →跑贏大盤 |
| 03/07/2023 | 156% | 古根海姆 | →$32 | 開始承保 | →購買 |
| 03/07/2023 | 212% | B of A證券 | →$39 | 開始承保 | →購買 |
| 03/07/2023 | 260% | Stifel | →$45 | 開始承保 | →購買 |
What is the target price for Mineralys Therapeutics (MLYS)?
Mineralys治療公司(MLYS)的目標價格是多少？
The latest price target for Mineralys Therapeutics (NASDAQ: MLYS) was reported by Credit Suisse on August 8, 2023. The analyst firm set a price target for $37.00 expecting MLYS to rise to within 12 months (a possible 196.00% upside). 9 analyst firms have reported ratings in the last year.
瑞士信貸於2023年8月8日報告了Mineralys治療公司(納斯達克：MLYS)的最新目標價。這家分析公司將目標價定為37美元，預計MLYS將在12個月內升至(可能上漲196.00)。去年有9家分析公司公佈了評級。
What is the most recent analyst rating for Mineralys Therapeutics (MLYS)?
Mineralys治療公司(MLYS)的最新分析師評級是多少？
The latest analyst rating for Mineralys Therapeutics (NASDAQ: MLYS) was provided by Credit Suisse, and Mineralys Therapeutics maintained their outperform rating.
對米納瑞斯治療公司(納斯達克代碼：MLYS)的最新分析師評級由瑞士信貸提供，米納瑞斯治療公司維持其表現優於大盤的評級。
When is the next analyst rating going to be posted or updated for Mineralys Therapeutics (MLYS)?
Mineralys治療公司(MLYS)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mineralys Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mineralys Therapeutics was filed on August 8, 2023 so you should expect the next rating to be made available sometime around August 8, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與Mineralys治療公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Mineralys治療公司的上一次評級是在2023年8月8日提交的，所以你應該預計下一次評級將在2024年8月8日左右提供。
Is the Analyst Rating Mineralys Therapeutics (MLYS) correct?
分析師對Mineralys Treeutics(MLYS)的評級正確嗎？
While ratings are subjective and will change, the latest Mineralys Therapeutics (MLYS) rating was a maintained with a price target of $38.00 to $37.00. The current price Mineralys Therapeutics (MLYS) is trading at is $12.50, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Mineralys治療公司(MLYS)評級保持不變，目標價在38.00美元至37.00美元之間。Mineralys治療公司(MLYS)目前的交易價格為12.50美元，超出了分析師的預測範圍。